Journal of Health Sciences and Medicine
Yazarlar: Fatih GÖKSEL
Konular:Sağlık Bilimleri ve Hizmetleri
DOI:10.32322/jhsm.663772
Anahtar Kelimeler:Bone,Metastasis,Palliative,Radiotherapy
Özet: Introduction: Bone metastasis is the first finding in 10-15% of cancer patients and seen in 30-90% of patients with cancer. Bone metastases are one of the most common causes of cancer-related pain. Radiotherapy (RT) is one of the first preferred palliation methods in bone metastases because it provides pain palliation in a short time, prevents the development of pathological fractures and creates minimal side effects. The aim of this study was to evaluate the diagnosis, demographic distribution and numerical status of patients with bone metastases who received palliative RT in terms of single center experiences. Material and Method: Patients who received palliative bone RT in Radiation Oncology Clinic Between January 2016 and September 2019 were included in the study. The Hospital Information Management System data of these patients were retrospectively scanned and the records obtained were used. All records were compared with the files in the archives and confirmed. The profiles, sex, age, histologic type, treatment schedule and fraction numbers of the patients who underwent radiotherapy for palliative purposes were retrospectively evaluated. Results: In this study, 1469 (14%) palliative bone RT patients of 10254 total radiotherapy patients were evaluated. In the last two years, there was no proportional decrease in the number of patients who received palliative bone RT. 48% of patients were female and 52% were male. According to the primary tumor distributions; breast cancers (31%), prostate cancers (17%), primary unknown cancers (15%), lung cancer (15%), GIS cancers (9%), bladder cancers (4%) and other cancers (10%). The median age of the patients was 60 (range 13-93). In the last 4 years, the most frequent 7 cancer diagnoses didn't show any significant gender and year-based changes. 888 palliative bone RT patients were treated with 2-5 fractions (60%), 420 patients with 6-10 fractions (29%) and 161 patients with single fraction (11%). There were also no significant changes in treatment schemes. The ratio of different dose-fraction schemes in our study is consistent with the literature. Conclusion: Optimal dose and fraction schemes are highly variable for palliative RT in patients with bone metastases. In light of these results, when deciding on palliative RT dose-fraction scheme; patient characteristics, treatment interactions, physical conditions, workload and economic costs should be taken into consideration. Palliative RT is the standard procedure in most patients with bone metastases because of its high palliation rate, short-term application, low toxicity and low re-application.